Articles tagged with Alzheimer Disease
A team of scientists has uncovered the amyloid precursor protein's modulating effect on neuronal signal transmission through binding to a specific receptor. This finding may lead to new treatments for Alzheimer's and other brain diseases.
Regenstrief Institute researcher Malaz Boustani advocates for Medicare payment for team-based care, which improves patient outcomes and reduces costs. Collaborative care models, including the Aging Brain Care model, have shown effective results in managing dementia and related dementias.
Researchers at Temple University Health System will test whether inhibiting a specific protein can stimulate new neuron growth. The goal is to understand the significance of reduced adult neurogenesis in Alzheimer's disease and potentially develop novel therapies.
Researchers found a link between decreased deep sleep and increased levels of the toxic brain protein tau, a hallmark of Alzheimer's disease. The study suggests that poor-quality sleep may be an early indicator of deteriorating brain health.
Researchers at Arizona State University discover that choline supplementation may help fight Alzheimer's disease in mice and their offspring. The study reveals that high choline intake during gestation and lactation improves spatial memory in subsequent generations, suggesting a transgenerational effect.
Researchers identified racial disparities in Alzheimer's disease diagnosis and progression among African-American participants, who had lower levels of brain protein tau. This may lead to under-recognition of the disease in African-Americans, as they often have lower tau levels than Caucasians, according to a new study.
A new study reveals that incorporating genetic diversity into a mouse model of Alzheimer's disease improves translatability, enabling more accurate predictions and potential treatments. The Resilience-Alzheimer's Disease Consortium has created a genetically diverse panel of mice with Alzheimer's mutations.
Neuronal cell death in Alzheimer's disease may be beneficial as it removes dysfunctional neurons, according to new research published in Cell Reports. The study suggests that the anti-aging mechanism of 'cell competition' plays a crucial role in protecting the brain from damage.
Researchers have developed an ultrasensitive test that detects tau protein clusters, which are associated with Alzheimer's disease and chronic traumatic encephalopathy. The test has been shown to detect the protein in small amounts of brain tissue, making it a major advance for early diagnosis.
Researchers identified associations between functional changes in certain brain cell types with Alzheimer's-related accumulation of phosphorylated tau protein. The study also showed that machine learning can be used to classify patients into different stages of disease pathogenesis based on gene expression patterns.
A study from Massachusetts General Hospital reveals that tau protein and amyloid-beta interact to impair brain function. Elevated tau levels were associated with reduced neural activity, regardless of tangle formation.
Researchers at FAU Brain Institute have received funding to study Alzheimer's disease and its effects on the brain, including detection methods and potential treatments. The $1.1 million grant will support studies in neuroscience and engineering to better understand and combat this devastating disease.
A European research project aims to uncover the physiological pathways underlying neurodegenerative diseases like Alzheimer's disease, Parkinson's disease, and Down syndrome, which are linked by evolving dementia. The HEROES project seeks to develop biomarkers for dementia progression and explore new therapeutic approaches.
Researchers discovered two tri-terpenoids, ursolic acid and lupeol, with potential activity against Alzheimer's disease pathology. Lupeol showed better binding affinity than ursolic acid, suggesting its potential as a BACE1 inhibitor for AD therapy.
A new study found that certain neurons protect themselves from Alzheimer's by clearing toxic tau proteins, which accumulate in sluggish cells. The discovery suggests new treatment possibilities to support natural defense mechanisms against neurodegenerative diseases.
Excitatory neurons are more susceptible to abnormal tau protein accumulation, a key factor in Alzheimer's disease progression. The study identifies genetic differences between excitatory and inhibitory neurons that may explain their vulnerability.
Researchers found that isolating symptoms to a single brain area resulted in low reproducibility rates, but analyzing symptom-specific circuitry within brain networks led to 100% reproducibility. This new approach aims to shed light on therapy development by identifying common symptom-localization patterns across different diseases.
A study published in BRAIN journal used a brain wiring diagram to reconcile inconsistent neuroimaging findings for Alzheimer's disease. The researchers found that all 26 studies reported abnormalities within the same connected brain network, improving reproducibility and understanding of the disease.
A comprehensive genomic study found that BACE1 and SIRT2 have significant roles in Alzheimer's disease progression, while ADAM10 and SIRT1 levels are lower in affected individuals. The study also reveals correlations between enzyme expression and cognitive performance scores.
Researchers have identified a single mutation in the MAPT gene as the culprit behind inherited frontotemporal dementia, leading to impaired communication between brain neurons and neurodegeneration. The study offers new potential treatment targets for both this condition and Alzheimer's disease.
The new guidelines aim to support doctors in assessing and managing patients with dementia who drive. Key findings indicate that many people with dementia are safe to drive in the early stages, but making the decision to stop can be difficult.
Researchers have identified three biomarkers in saliva samples to detect mild cognitive impairment and Alzheimer's disease. The study uses metabolomics to analyze over 6,000 compounds, showing promising results for a potential clinical test.
A recent study reveals a significant increase in worldwide dementia cases over the past 26 years, with the number of people suffering from Alzheimer's disease and other dementias rising to 43.8 million in 2016. This represents a 117% growth, attributed to both aging and global population growth.
The five-year study will investigate the use of electroconvulsive therapy (ECT) to treat severe agitation and aggression in people with Alzheimer's disease. Researchers will compare ECT treatment plus standard therapies to standard therapies alone for individuals with moderate-to-severe Alzheimer's dementia.
Researchers have identified three promising radiopharmaceuticals that bind to tau tangles, a protein associated with neurodegenerative diseases. The tracers were tested in patients with Alzheimer's disease and found to show promise in measuring tau protein accumulation.
A study found that using two memory tests to assess episodic memory improves the accuracy of diagnosing mild cognitive impairment due to Alzheimer's disease. Those who performed poorly in both tests showed faster brain atrophy, highlighting the importance of comprehensive neuropsychological assessment.
A comprehensive review highlights novel approaches to slow or prevent Alzheimer's disease, focusing on the effects of aging on the brain. Combination therapy is deemed necessary for better treatment outcomes, similar to other major diseases.
Researchers at Brigham and Women's Hospital have developed a blood test that detects different populations of tau fragments, which are specifically elevated in Alzheimer's disease. The test has shown promise in initial studies with high diagnostic sensitivity and specificity, but further validation is needed to confirm its effectiveness.
A CWRU researcher has secured a $14.6 million grant to study Alzheimer's disease in diverse populations, including African-Americans and Hispanics. The project aims to identify new genetic factors and improve understanding of the disease's impact on these communities.
A new second-generation positron emission tomography (PET) tracer has been identified for imaging tau pathology in Alzheimer's disease patients. The tracer, 18F-RO-948, showed promising results in a human evaluation study, outperforming other novel tau-specific radiopharmaceuticals.
Researchers identified six distinct subgroups of Alzheimer's patients based on cognitive functioning and genetic data. The study found substantial biological differences among these subgroups, which may lead to the development of precision medicine approaches for Alzheimer's disease.
Researchers found that female mice with Alzheimer's-like pathology spent more time in stages with high estrogen levels than control mice, associated with impaired learning and memory. Beta-amyloid production also increased during these stages, highlighting the importance of female biology in nervous system disorders.
New research from King's College London identifies changes in memory and attention as earliest signs of Alzheimer's in Down syndrome, paving the way for prevention trials. The study suggests that treatments could delay symptoms if started in the mid-30s with relatively low participant numbers.
Researchers have used magnetoencephalography to measure magnetite levels in the human brain, which could lead to new studies on its role in neurodegenerative diseases. The study found greater accumulation of magnetite in the brains of older individuals, primarily in the hippocampus.
Bruno Jedynak, a PSU math and statistics professor, has been awarded nearly $500K to continue his research on the largest family history study of Alzheimer's disease. The study involves over 1,580 middle-aged participants and aims to understand the disease's progression by identifying biomarkers.
Researchers used MRI brain scans to predict Alzheimer's disease, achieving 89% accuracy in identifying patients at risk. The study found that diffusion tensor imaging (DTI) identified quantifiable differences in the brains of those who developed the disease.
Researchers used diffusion tensor imaging to assess white matter health and found that individuals who went on to experience cognitive decline had significantly more signs of damage. The study predicted cognitive decline with 89% accuracy, rising to 95% when focusing on specific brain areas.
A study from the University of Eastern Finland found that one in five people with Alzheimer's disease use benzodiazepines and opioids concurrently. Prolonged use was linked to lung diseases, osteoporosis, and fractures.
A recent study by Baycrest researchers found that individuals with mild cognitive impairment and primary progressive aphasia exhibited sluggish brainwaves and subtle signs of damage in memory and planning regions. These slowing brainwaves predicted the severity of their condition, such as degree of memory loss.
The National Institutes of Health has awarded Professor Hillard Kaplan's project a total of $6.9 million to study the prevalence and causes of Alzheimer's disease among the Tsimane people in Bolivia. The research will explore the relationship between lifestyle, diet, and exercise on dementia risk in two Native American populations.
A new subclass of compounds, dubbed geroneuroprotectors (GNPs), has been identified as potential AD drug candidates and slow the aging process in mice. The study suggests that these compounds could provide therapeutic benefits for Alzheimer's disease and other diseases associated with aging.
Researchers developed a precision-medicine platform that uses genomic data, biospecimen measurements, and other inputs to create personalized treatment plans for mild Alzheimer's disease and at-risk individuals. The study showed significant improvements in memory function scores for 80% of participants.
Researchers at CWRU are using big data methods to understand the mechanisms of Alzheimer's disease. They're developing large-scale knowledge bases that will identify ways to develop new or reuse existing drugs, with a focus on identifying possible new genes and pathways.
Researchers identified 90 genetic points associated with increased risk for both cardiovascular disease and Alzheimer's, including genes involved in lipid metabolism. The study found that targeting these genes may help lower Alzheimer's risk by managing cholesterol and triglyceride levels.
Researchers found microscopic neuropathology and neurophysiological changes in a rat model of mild traumatic brain injury. The study suggests that even mild exposure to a single blast shock wave can induce pathogenic effects that accumulate over time.
Researchers found shared genetic factors between Alzheimer's disease and high blood lipid levels, suggesting potential for early diagnosis and targeted therapies. The study analyzed 1.5 million individuals and identified specific DNA variants that increase the risk of developing both conditions.
A multidisciplinary team at Salk Institute will investigate mechanisms underlying Alzheimer's disease and aging-related cognitive decline using cutting-edge methods and machine-learning algorithms. The goal is to identify new targets for therapeutic research and biomarkers of early stage cognitive decline.
A new study by the University of Exeter found that most people living with dementia also have at least one additional chronic health condition. The study, led by Professor Linda Clare, highlights the need for better care planning and support to deal with multiple conditions in a more integrated way.
A new study published in Radiology uses deep learning to predict Alzheimer's disease from brain imaging, achieving 100% sensitivity in detecting the disease an average of more than six years prior to final diagnosis. The algorithm has the potential to complement existing tests and provide opportunities for early intervention.
A recent study suggests that drinking coffee may protect against both Alzheimer's and Parkinson's diseases. The research found that phenylindanes, compounds present in dark roasted coffee, inhibit the formation of beta amyloid and tau protein fragments, which are common in these diseases.
Breakdowns in brain's blood vessels linked to Alzheimer's disease and vascular dementia, potentially leading to earlier diagnosis and intervention through biomarkers, exercise, and targeted treatments. Age-related loss of brain lymphatic function also plays a role in neurodegeneration.
Researchers found that a pharmacological inhibitor of HDAC3 reduced amyloid-beta in vulnerable brain regions and improved memory in a transgenic mouse model of Alzheimer's disease. The study suggests that HDAC3 represents a potential drug target for several hallmarks of AD.
Researchers found that people with Alzheimer's disease who were treated with diabetes drugs showed fewer markers of the disease, including abnormal microvasculature and gene expressions. The study suggests targeting the brain's capillary system could have beneficial effects in Alzheimer's patients, opening opportunities for new therapies.
The Alzheimer's Association has awarded six international researchers with $1 million each over two years to explore innovative treatments for early-stage Alzheimer's disease. The goal is to discover effective drugs that can rejuvenate brain cells and slow or halt the progression of the disease.
Exercise has been shown to decrease fall risk among older adults with Alzheimer's disease and neuropsychiatric symptoms. The study found that those who exercised had a lower risk of falls compared to non-exercising individuals, while also highlighting the increased risk for falls in those with depression and anxiety.
Two studies using optical coherence tomography angiography (OCTA) reveal altered retinal blood vessels in patients with Alzheimer's disease, even before symptoms appear. Researchers hope this new method will enable early detection and treatment of the condition.
A new center will recruit and train junior scientists to study Alzheimer's disease in Native populations, with a focus on American Indian, Alaska Native, and Pacific Islander investigators. The center aims to fill knowledge gaps and promote prevention and treatment to reduce health disparities.
Researchers from Regenstrief Institute and Indiana University Center for Aging Research develop IN-PEACE to improve dementia care and reduce caregiver stress through state-of-the-art symptom management. The initiative provides support by nurses and social workers to both patients and their family caregivers.
Research associates higher cortisol levels with impaired memory and reduced brain volume in middle-aged adults. Cognitive data from the Framingham Heart Study found that morning cortisol levels predicted worse brain structure and cognition.
Researchers found that osteocalcin, a bone hormone, reverses memory loss in the aging brain by interacting with key proteins like RbAp48. Exercise may also positively affect the brain through osteocalcin release, suggesting a potential way to stave off age-related memory loss.